Efficacy and safety of sitafloxacin (STFX) for low-risk febrile neutropenia in patients with lung cancer, phase II study,
Phase 2
- Conditions
- febrile neutropenia
- Registration Number
- JPRN-UMIN000010911
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patient who is too severely ill 2. A history of renal failure (S-Cr of 2.0 mg/dl or above) 3. A known history of hypersensitivity to fluoroquinolones 4. A known history of allergy 5. Patient who is not evaluated for response 6. Pregnant or lactating women. 7. Patients administered with prohibiting medication (such as other antibiotics, gamma-globulin, corticosteroid) 8.patient who is judged as an inappropriate case by the doctor in charge
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method